» Articles » PMID: 24698732

Multi-marker Analysis of Circulating Cell-free DNA Toward Personalized Medicine for Colorectal Cancer

Overview
Journal Mol Oncol
Date 2014 Apr 5
PMID 24698732
Citations 99
Authors
Affiliations
Soon will be listed here.
Abstract

Development of a Q-PCR-based assay for the high-performance analysis of circulating cell-free DNA (ccfDNA) requires good knowledge of its structure and size. In this work, we present the first visual determination of ccfDNA by Atomic Force Microscopy (AFM) on plasma samples from colorectal cancer (CRC) patients and healthy donors. In addition to the examination of fragment size distribution profile as performed by Q-PCR, this analysis confirms that ccfDNA is highly fragmented and that more than 80% of ccfDNA fragments in CRC plasma are below 145 bp. We adapted an Allele-Specific Blocker (ASB) Q-PCR to small ccfDNA fragments to determine simultaneously the total ccfDNA concentration, the presence of point mutation, the proportion of mutated allele, and a ccfDNA integrity index. The data validated analytically these four parameters in 124 CRC clinical samples and 71 healthy individuals. The multi-marker method, termed Intplex, enables sensitive and specific non-invasive analysis of tumor ccfDNA, which has great potential in terms of cost, quality control, and easy implementation in every clinical center laboratory.

Citing Articles

Establishment of liquid biopsy procedure for the analysis of circulating cell free DNA, exosomes, RNA and proteins in colorectal cancer and adenoma patients.

ceri A, Somborac-Bacura A, Fabijanec M, Hulina-Tomaskovic A, Matusina M, Detel D Sci Rep. 2024; 14(1):26925.

PMID: 39506031 PMC: 11541997. DOI: 10.1038/s41598-024-78497-x.


Detection of Circulating Tumor DNA in Lymphoma Patients.

Bruscaggin A, Pini K, Rossi D Methods Mol Biol. 2024; 2865:475-490.

PMID: 39424738 DOI: 10.1007/978-1-0716-4188-0_21.


Integrated molecular profiling of , mutations, and mismatch repair status in advanced colorectal carcinoma: insights from gender and tumor laterality.

Remonatto G, Pilar E, de-Paris F, Schaefer P, Kliemann L J Gastrointest Oncol. 2024; 15(4):1580-1591.

PMID: 39279928 PMC: 11399832. DOI: 10.21037/jgo-23-1017.


Cell-free nucleic acid fragmentomics: A non-invasive window into cellular epigenomes.

Sirajee A, Kabiraj D, De S Transl Oncol. 2024; 49:102085.

PMID: 39178576 PMC: 11388671. DOI: 10.1016/j.tranon.2024.102085.


Association of the immediate perioperative dynamics of circulating DNA levels and neutrophil extracellular traps formation in cancer patients.

Kudriavtsev A, Pastor B, Mirandola A, Pisareva E, Gricourt Y, Capdevila X Precis Clin Med. 2024; 7(2):pbae008.

PMID: 38699382 PMC: 11062027. DOI: 10.1093/pcmedi/pbae008.


References
1.
Jung K, Fleischhacker M, Rabien A . Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. Clin Chim Acta. 2010; 411(21-22):1611-24. DOI: 10.1016/j.cca.2010.07.032. View

2.
Dawson S, Tsui D, Murtaza M, Biggs H, Rueda O, Chin S . Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368(13):1199-209. DOI: 10.1056/NEJMoa1213261. View

3.
Leon S, Shapiro B, SKLAROFF D, Yaros M . Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977; 37(3):646-50. View

4.
Lievre A, Bachet J, Le Corre D, Boige V, Landi B, Emile J . KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006; 66(8):3992-5. DOI: 10.1158/0008-5472.CAN-06-0191. View

5.
Mouliere F, El Messaoudi S, Gongora C, Guedj A, Robert B, Del Rio M . Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. Transl Oncol. 2013; 6(3):319-28. PMC: 3660801. DOI: 10.1593/tlo.12445. View